Yesterday’s article, Pre-American Society Of Hematology (ASH) News Starting To Break, featured the first part of Millennium Pharmaceutical’s Curtainraiser ASH Preview Press Release.
Here is a preview of major studies involving Velcade which will be presented at ASH:
HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)
Presenter: Pieter Sonneveld, M.D., University Hospital, Rotterdam, The Netherlands
Abstract #40: Oral Presentation, Sunday, December 5, 5:15 pm ET
This Phase III head-to-head, randomized study compared VELCADE maintenance to an immunodulatory agent maintenance in the front-line setting. Endpoints included progression-free survival, overall survival, response and safety.
Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients
Presenter: Ruben Niesvizky, M.D., Weill Cornell Medical College, New York, NY
Abstract #619: Oral Presentation, Monday, December 6, 2:45 pm ET
The UPFRONT study is a U.S. community-based, randomized, open-label, multicenter Phase IIIb trial comparing three VELCADE based combinations followed by VELCADE maintenance in front-line multiple myeloma. Endpoints included profession-free survival, response rate, safety and tolerability.
A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma
Presenter: Philippe Moreau, University Hospital, Nantes, France
Abstract #312: Oral Presentation, Monday, December 6, 8:15 am ET
This multi-center, international, randomized Phase III trial compared intravenous to subcutaneous administration of VELCADE. Endpoints included response rate, one-year overall survival, duration of response and time to progression.
Of course, Millennium is not only focusing on multiple myeloma. You can see a preview of research centering on several types of lymphoma and leukemia by going to: American Society Of Hematology Meetings To Feature Latest Advances In Blood Cancer Research.
Lots to cover and lots to learn! I had better get to work.
Feel good and keep smiling! Pat